The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Genentech has withdrawn its psoriasis drug Raptiva (efalizumab) from US shelves on continuing concerns about its link to the brain disease progressive multifocal leukoencephalopathy (PML).
Irish drugmaker Elan is considering a separate stock exchange
listing for its contract services unit, Elan Drug Technology,
according to comments by executives at its recent annual general
meeting.
US biotechnology company Biogen Idec has said that it plans to sell
a California manufacturing plant built to produce its withdrawn
multiple sclerosis drug Tysabri (natalizumab) to Genentech,
reports Phil Taylor.
